Indivior Pharmaceuticals (INDV) Cash & Equivalents (2021 - 2026)
Indivior Pharmaceuticals (INDV) posted quarterly Cash & Equivalents of $175.0 million for Q1 2026, down 52.96% year-over-year from $372.0 million in Q1 2025, and down 10.26% quarter-over-quarter from $195.0 million in Q4 2025.
Indivior Pharmaceuticals (INDV) Cash & Equivalents (2021 - 2026) Analysis & Trends
Indivior Pharmaceuticals' Cash & Equivalents history runs 6 years deep, the most recent figure standing at $175.0 million for Q1 2026.
- In Q1 2026, Cash & Equivalents fell 52.96% year-over-year to $175.0 million; the TTM figure through Mar 2026 stood at $175.0 million (down 52.96% YoY), while the FY2025 annual figure was $195.0 million, down 38.87% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $175.0 million, down from $195.0 million in the prior quarter.
- The five-year high for Cash & Equivalents was $774.0 million in Q4 2022, with the low at $175.0 million in Q1 2026.
- The 5-year median for Cash & Equivalents is $345.5 million (2024), against an average of $388.2 million.
- The sharpest annual moves came in 2023 and 2024: Cash & Equivalents sank 59.17% in 2023, then grew 0.95% in 2024.
- Indivior Pharmaceuticals' Cash & Equivalents stood at $774.0 million in 2022, then tumbled by 59.17% to $316.0 million in 2023, then rose by 0.95% to $319.0 million in 2024, then sank by 38.87% to $195.0 million in 2025, then slipped by 10.26% to $175.0 million in 2026.
- Business Quant data shows INDV's Cash & Equivalents at $175.0 million in Q1 2026, $195.0 million in Q4 2025, and $445.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | 1.11 Bn |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn | 1.48 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn | 2.89 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 1.80 Bn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 332.40 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | 164.00 Mn |
| 10 | Indivior Pharmaceuticals | 4.58 Bn | 4.36 Bn | 294.00 Mn | 222.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 222.00 Mn |
| Mar 31, 2026 | 175.00 Mn |
| Dec 31, 2025 | 195.00 Mn |
| Sep 30, 2025 | 445.00 Mn |
| Jun 30, 2025 | 510.00 Mn |
| Mar 31, 2025 | 372.00 Mn |
| Dec 31, 2024 | 319.00 Mn |
| Dec 31, 2023 | 316.00 Mn |
| Dec 31, 2022 | 774.00 Mn |
| Dec 31, 2021 | 1.10 Bn |